Article
Pathology
Natalie Banet, Maryam Shahi, Denise Batista, Raluca Yonescu, Edward J. Tanner, Amanda N. Fader, Ashley Cimino-Mathews
Summary: HER-2 targeted therapy shows promising results in HER-2-positive uterine serous carcinoma, but evaluating HER-2 status can be challenging due to intratumoral heterogeneity and discordance between IHC and FISH results, highlighting the need for further research and caution in clinical practice.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2021)
Review
Oncology
Blair Mcnamara, Levent Mutlu, Michelle Greenman, Justin Harold, Alessandro Santin
Summary: Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) are rare and aggressive forms of uterine cancer, with specific mutations that can be targeted by HER2-targeting therapies. This article summarizes the evidence and ongoing clinical trials for these targeted therapies.
Article
Pathology
Taylor M. Jenkins, Leigh A. Cantrell, Mark H. Stoler, Anne M. Mills
Summary: HER2 overexpression and amplification are present in a subset of uterine carcinosarcomas (UCS), which may influence the response to HER2-targeted therapies. HER2-positive UCS may be less susceptible to immune checkpoint inhibitors. Therefore, HER2-targeted therapies could be clinically beneficial for a subset of UCS patients without other treatment options.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2022)
Article
Reproductive Biology
Maho Shimizu, Keitaro Yamanaka, Maho Azumi, Masako Tomimoto, Keiichi Washio, Ryosuke Takahashi, Satoshi Nagamata, Yuka Murata, Yui Yamasaki, Yoshito Terai
Summary: The case presented a patient with SEIC accompanied by serous ovarian carcinoma and lymph node metastasis. The difficulty in identifying the primary lesion was highlighted as both tumors were serous carcinomas. Further development of methods for differentiation between the diseases is needed due to controversial histological diagnostic criteria.
JOURNAL OF OVARIAN RESEARCH
(2021)
Review
Obstetrics & Gynecology
Antonio Raffone, Antonio Travaglino, Diego Raimondo, Manuela Maletta, Valentino De Vivo, Umberto Visiello, Paolo Casadio, Renato Seracchioli, Fulvio Zullo, Luigi Insabato, Antonio Mollo
Summary: A systematic review and meta-analysis showed that compared to SC and CCC, UCS has a significantly worse prognosis with a 1.5-1.6-fold increased risk of death. This suggests the need for more aggressive treatment for UCS compared to SC and CCC. Further studies are necessary to define the prognostic impact of different molecular subgroups.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Takayuki Mori, Hiroki Kato, Masaya Kawaguchi, Yuichiro Hatano, Takuma Ishihara, Yoshifumi Noda, Fuminori Hyodo, Masayuki Matsuo, Tatsuro Furui, Ken-ichirou Morishige
Summary: This study aimed to evaluate the MRI findings of different types of endometrial cancer. Serous carcinoma (SC) showed heterogeneous signal with peritoneal dissemination and abnormal ascites, while clear cell carcinoma (CCC) exhibited larger tumor size, higher ADC values, infiltrative growth pattern, heterogeneous signal, and abnormal ascites.
EUROPEAN RADIOLOGY
(2022)
Article
Medicine, General & Internal
Hyunjin Kim, Kiyong Na, Go Eun Bae, Hyun-Soo Kim
Summary: Research on mesonephric-like adenocarcinoma of the uterine corpus revealed irregularities in immunohistochemical staining, posing challenges for differential diagnosis. Caution should be taken when interpreting immunohistochemical staining results.
Article
Biochemistry & Molecular Biology
Stefania Bellone, Blair McNamara, Levent Mutlu, Cem Demirkiran, Tobias Max Philipp Hartwich, Justin Harold, Yang Yang-Hartwich, Eric R. Siegel, Alessandro D. Santin
Summary: The use of personalized circulating tumor DNA markers can potentially detect residual tumors and early recurrences in patients with uterine serous carcinoma and carcinosarcomas, leading to earlier treatment and changing clinical practice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Genetics & Heredity
Munan Zhao, Wei Li
Summary: A new classification of UCEC based on metabolic patterns was established, identifying two metabolic subtypes with distinct characteristics in prognosis, immune infiltration, genetic alteration, and responses to immunotherapy. Furthermore, a model with three gene metabolism-related signatures was developed to predict prognosis.
FRONTIERS IN GENETICS
(2023)
Article
Multidisciplinary Sciences
Igor Govorov, Sanaz Attarha, Larysa Kovalevska, Emil Andersson, Elena Kashuba, Miriam Mints
Summary: The expression of STK4 in endometrial cancer (EC) is associated with patient prognosis, particularly in serous tumors where higher expression is correlated with worse prognosis. The determination of STK4 expression pattern could serve as a potential prognostic marker for serous EC.
SCIENTIFIC REPORTS
(2022)
Article
Obstetrics & Gynecology
Samuel Grindstaff, Linda C. Hanley, Natalie Banet
Summary: We report a rare case of yolk sac tumor in a uterine carcinosarcoma with a mixture of epithelial components, along with corresponding immune and therapeutic markers.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
(2022)
Article
Obstetrics & Gynecology
Samuel Grindstaff, Linda C. Hanley, Natalie Banet
Summary: We report a case of yolk sac tumor arising in a uterine carcinosarcoma, exhibiting both endometrioid and serous components in the carcinomatous tissue, and homologous (spindled) differentiation in the sarcomatous tissue. This is the first report of a carcinosarcoma with such a mixture of epithelial components, and the corresponding immune and therapeutic markers were analyzed.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
(2022)
Article
Oncology
Jehan B. Yahya, Simeng Zhu, Charlotte Burmeister, Miriana Y. Hijaz, Mohamed A. Elshaikh
Summary: This study compared survival endpoints between women with uterine carcinosarcoma and uterine serous carcinoma, and found no significant difference in survival rates between the two groups in early-stage disease. Adjuvant combined modality treatment was shown to significantly improve recurrence-free survival and overall survival.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2021)
Article
Pathology
Hiroshi Yoshida, Yuka Asami, Mayumi Kobayashi-Kato, Yasuhito Tanase, Masaya Uno, Mitsuya Ishikawa, Kouya Shiraishi, Tomoyasu Kato
Summary: This study aimed to clarify the genetic features of endometrioid-type endometrial cancer arising in adenomyosis (EC-AIA) using targeted sequencing and immunohistochemistry (IHC). Three endometrioid-type EC-AIAs were identified, with more gene mutations in carcinoma compared to adjacent adenomyosis tissues. These molecular alterations suggest a similar carcinogenesis to a subset of endometrial endometrioid carcinoma and may serve as potential targets for liquid biopsy in the future.
Article
Pathology
Hisham Assem, Douglas Rottmann, Alexander Finkelstein, Minhua Wang, Elena Ratner, Alessandro D. Santin, Natalia Buza, Pei Hui
Summary: This study found that MUSCs confined to endometrial polyps have lower rates of extrauterine disease, lymphovascular invasion, and lymph node metastasis compared to nonpolyp confined tumors. Patients with MUSC confined to polyps also have a better prognosis and lower risk of high-stage disease at presentation.
Article
Oncology
Milana A. Bergamino, Gabriele Morani, Joel Parker, Eugene F. Schuster, Mariana F. Leal, Elena Lopez-Knowles, Holly Tovey, Judith M. Bliss, John F. R. Robertson, Ian E. Smith, Mitch Dowsett, Maggie C. U. Cheang
Summary: The duration of neoadjuvant endocrine therapy (NET) has an impact on the molecular characteristics of breast cancer. Short-term (2 weeks) and longer-term neoadjuvant AI treatment show different gene expression profiles. Changes in HER2-enriched and Luminal B subtypes are similar between the two cohorts, and AI-sensitive tumors associated with good survival may be identified after 2 weeks of AI. The changes in immune-checkpoint component expression in early AI resistance and its impact on survival outcome need further investigation.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Mitch Dowsett, Lucy Kilburn, Mothaffar F. Rimawi, C. Kent Osborne, Katherine Pogue-Geile, Yuan Liu, Samuel A. Jacobs, Melanie Finnigan, Shannon Puhalla, Andrew Dodson, Vera Martins, Maggie Cheang, Sophie Perry, Chris Holcombe, Nick Turner, Claire Swift, Judith M. Bliss, Stephen Johnston
Summary: In postmenopausal women with ER+/HER2(-) primary breast cancer, higher ER and PgR levels were associated with a greater chance of complete cell-cycle arrest, while higher Ki67, c-PARP, and CCNE1 levels were associated with a lower chance. Letrozole decreased CCND1 levels, but palbociclib showed a tendency to increase them. Ki67 recovery within 3-9 days after stopping palbociclib indicates incomplete suppression of proliferation during the off week.
CLINICAL CANCER RESEARCH
(2022)
Meeting Abstract
Oncology
Milana A. Bergamino Sirven, Elena Lopez-Knowles, Gabriele Morani, Holly Tovey, Lucy Kilburn, Chris Holcombe, Anthony Skene, Ian Smith, John Robertson, Gene Schuster, Judith M. Bliss, Mitch Dowsett, Maggie C. U. Cheang
Correction
Oncology
Aruna Korlimarla, P. S. Hari, Jyoti Prabhu, Chanthirika Ragulan, Yatish Patil, V. P. Snijesh, Krisha Desai, Aju Mathews, Sandhya Appachu, Ravi B. Diwakar, B. S. Srinath, Alan Melcher, Maggie Cheang, Anguraj Sadanandam
TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Holly Tovey, Orsolya Sipos, Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, Maggie Chon U. Cheang
Summary: This study explored the predictive ability of DNA damage response (DDR) and immune markers in the treatment response of triple-negative breast cancer. High immune features predict response to docetaxel, while high DDR signature scores predict response to carboplatin. Patients can be divided into different subgroups based on their treatment sensitivity. Caution is needed when using transcriptional signatures derived from primary tumors to guide treatment.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Jeppe Thagaard, Glenn Broeckx, David B. Page, Chowdhury Arif Jahangir, Sara Verbandt, Zuzana Kos, Rajarsi Gupta, Reena Khiroya, Khalid Abduljabbar, Gabriela Acosta Haab, Balazs Acs, Guray Akturk, Jonas S. Almeida, Isabel Alvarado-Cabrero, Mohamed Amgad, Farid Azmoudeh-Ardalan, Sunil Badve, Nurkhairul Bariyah Baharun, Eva Balslev, Enrique R. Bellolio, Vydehi Bheemaraju, Kim R. M. Blenman, Luciana Botinelly Mendonca Fujimoto, Najat Bouchmaa, Octavio Burgues, Alexandros Chardas, Maggie U. Cheang, Francesco Ciompi, Lee A. D. Cooper, An Coosemans, German Corredor, Anders B. Dahl, Flavio Luis Dantas Portela, Frederik Deman, Sandra Demaria, Johan Dore Hansen, Sarah N. Dudgeon, Thomas Ebstrup, Mahmoud Elghazawy, Claudio Fernandez-Martin, Stephen B. Fox, William M. Gallagher, Jennifer M. Giltnane, Sacha Gnjatic, Paula Gonzalez-Ericsson, Anita Grigoriadis, Niels Halama, Matthew G. Hanna, Aparna Harbhajanka, Steven N. Hart, Johan Hartman, Soren Hauberg, Stephen Hewitt, Akira Hida, Hugo M. Horlings, Zaheed Husain, Evangelos Hytopoulos, Sheeba Irshad, Emiel A. M. Janssen, Mohamed Kahila, Tatsuki R. Kataoka, Kosuke Kawaguchi, Durga Kharidehal, Andrey Khramtsov, Umay Kiraz, Pawan Kirtani, Liudmila L. Kodach, Konstanty Korski, Aniko Kovacs, Anne-Vibeke Laenkholm, Corinna Lang-Schwarz, Denis Larsimont, Jochen K. Lennerz, Marvin Lerousseau, Xiaoxian Li, Amy Ly, Anant Madabhushi, Sai K. Maley, Vidya Manur Narasimhamurthy, Douglas K. Marks, Elizabeth S. McDonald, Ravi Mehrotra, Stefan Michiels, Fayyaz ul Amir Afsar Minhas, Shachi Mittal, David A. Moore, Shamim Mushtaq, Hussain Nighat, Thomas Papathomas, Frederique Penault-Llorca, Rashindrie D. Perera, Christopher J. Pinard, Juan Carlos Pinto-Cardenas, Giancarlo Pruneri, Lajos Pusztai, Arman Rahman, Nasir Mahmood Rajpoot, Bernardo Leon Rapoport, Tilman T. Rau, Jorge S. Reis-Filho, Joana M. Ribeiro, David Rimm, Anne Roslind, Anne Vincent-Salomon, Manuel Salto-Tellez, Joel Saltz, Shahin Sayed, Ely Scott, Kalliopi P. Siziopikou, Christos Sotiriou, Albrecht Stenzinger, Maher A. Sughayer, Daniel Sur, Susan Fineberg, Fraser Symmans, Sunao Tanaka, Timothy Taxter, Sabine Tejpar, Jonas Teuwen, E. Aubrey Thompson, Trine Tramm, William T. Tran, Jeroen van Der Laak, Paul J. van Diest, Gregory E. Verghese, Giuseppe Viale, Michael Vieth, Noorul Wahab, Thomas Walter, Yannick Waumans, Hannah Y. Wen, Wentao Yang, Yinyin Yuan, Reena Md Zin, Sylvia Adams, John Bartlett, Sibylle Loibl, Carsten Denkert, Peter Savas, Sherene Loi, Roberto Salgado, Elisabeth Specht Stovgaard
Summary: The clinical significance of tumor-immune interaction in breast cancer has been established. Tumor-infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple-negative and HER2-positive breast cancer. The use of machine learning (ML) to automatically evaluate TILs has shown promising results. However, there are challenges in implementing this in trial and routine clinical management, including technical slide issues, ML and image analysis aspects, data challenges, and validation issues.
JOURNAL OF PATHOLOGY
(2023)
Review
Oncology
David B. Page, Glenn Broeckx, Chowdhury Arif Jahangir, Chowdhury Jahangir, Sara Verbandt, Rajarsi R. Gupta, Jeppe Thagaard, Reena Khiroya, Zuzana Kos, Khalid Abduljabbar, Gabriela Acosta Haab, Balazs Acs, Jonas S. Almeida, Isabel Alvarado-Cabrero, Farid Azmoudeh-Ardalan, Sunil Badve, Nurkhairul Bariyah Baharun, Enrique R. Bellolio, Vydehi Bheemaraju, Kim R. M. Blenman, Luciana Botinelly Mendonca Fujimoto, Octavio Burgues, Maggie Chon U. Cheang, Francesco Ciompi, Lee A. D. Cooper, An Coosemans, German Corredor, Flavio Luis Dantas Portela, Frederik Deman, Sandra Demaria, Sarah N. Dudgeon, Mahmoud Elghazawy, Scott Ely, Claudio Fernandez-Martin, Susan Fineberg, Stephen B. Fox, William M. Gallagher, Jennifer M. Giltnane, Sacha Gnjatic, Paula Gonzalez-Ericsson, Anita Grigoriadis, Niels Halama, Matthew G. Hanna, Aparna Harbhajanka, Alexandros Hardas, Steven N. Hart, Johan Hartman, Stephen Hewitt, Akira Hida, Hugo M. Horlings, Zaheed Husain, Evangelos Hytopoulos, Sheeba Irshad, Emiel A. M. Janssen, Mohamed Kahila, Tatsuki R. Kataoka, Kosuke Kawaguchi, Durga Kharidehal, Andrey Khramtsov, Umay Kiraz, Pawan Kirtani, Liudmila L. Kodach, Konstanty Korski, Aniko Kovacs, Anne-Vibeke Laenkholm, Corinna Lang-Schwarz, Denis Larsimont, Jochen K. Lennerz, Marvin Lerousseau, Xiaoxian Li, Amy Ly, Anant Madabhushi, Sai K. Maley, Vidya Manur Narasimhamurthy, Douglas K. Marks, Elizabeth S. McDonald, Ravi Mehrotra, Stefan Michiels, Fayyaz ul Amir Afsar Minhas, Shachi Mittal, David A. Moore, Shamim Mushtaq, Hussain Nighat, Thomas Papathomas, Frederique Penault-Llorca, Rashindrie D. Perera, Christopher J. Pinard, Juan Carlos Pinto-Cardenas, Giancarlo Pruneri, Lajos Pusztai, Arman Rahman, Nasir Mahmood Rajpoot, Bernardo Leon Rapoport, Tilman T. Rau, Jorge S. Reis-Filho, Joana M. Ribeiro, David Rimm, Anne-Vincent Salomon, Manuel Salto-Tellez, Joel Saltz, Shahin Sayed, Kalliopi P. Siziopikou, Christos Sotiriou, Albrecht Stenzinger, Maher A. Sughayer, Daniel Sur, Fraser Symmans, Sunao Tanaka, Timothy Taxter, Sabine Tejpar, Jonas Teuwen, E. Aubrey Thompson, Trine Tramm, William T. Tran, Jeroen van Der Laak, Paul J. van Diest, Gregory E. Verghese, Giuseppe Viale, Michael Vieth, Noorul Wahab, Thomas Walter, Yannick Waumans, Hannah Y. Wen, Wentao Yang, Yinyin Yuan, Sylvia Adams, John Mark Seaverns Bartlett, Sibylle Loibl, Carsten Denkert, Peter Savas, Sherene Loi, Roberto Salgado, Elisabeth Specht Stovgaard, Guray Akturk, Najat Bouchmaa
Summary: Modern histologic imaging platforms combined with machine learning methods offer new opportunities for studying the spatial distribution of immune cells in the tumor microenvironment. However, there is currently no standardized method for describing or analyzing spatial immune cell data, and most previous spatial analyses have been simplistic. In this review, two approaches (raster versus vector-based) for reporting and analyzing spatial data are outlined, along with a summary of reported spatial immune cell metrics and their prognostic associations in various cancers. Two well-described clinical biomarkers, the breast cancer stromal tumor infiltrating lymphocytes score and the colon cancer Immunoscore, are also discussed, along with potential research opportunities to improve the clinical utility of these spatial biomarkers.
JOURNAL OF PATHOLOGY
(2023)
Article
Multidisciplinary Sciences
Eugene F. Schuster, Elena Lopez-Knowles, Anastasia Alataki, Lila Zabaglo, Elizabeth Folkerd, David Evans, Kally Sidhu, Maggie Chon U. Cheang, Holly Tovey, Manuel Salto-Tellez, Perry Maxwell, John Robertson, Ian Smith, Judith M. Bliss, Mitch Dowsett
Summary: This study conducts a large-scale molecular analysis to compare the response of ER + HER2- breast cancer patients to aromatase inhibitors (AIs). It identifies low ESR1 levels as a predictor for poor response, with high proliferation, expression of growth factor pathways, and non-luminal subtypes. Additionally, it indicates that patients with high ESR1 expression have similar proportions of luminal subtypes to good responders, but lower plasma estradiol levels, lower expression of estrogen response genes, higher levels of tumor infiltrating lymphocytes and immune markers, and more TP53 mutations.
NATURE COMMUNICATIONS
(2023)
Article
Multidisciplinary Sciences
Jessica P. Burns, Christopher Wilding, Lukas Krasny, Xixuan Zhu, Madhumeeta Chadha, Yuen Bun Tam, P. S. H. Hari, Aswanth Mahalingam, Alexander T. J. Lee, Amani Arthur, Nafia Guljar, Emma Perkins, Valeriya Pankova, Andrew Jenks, Vanessa Djabatey, Cornelia Szecsei, Frank McCarthy, Chanthirika Ragulan, Martina I. Milighetti, Theodoros Roumeliotis, Stephen Crosier, Martina S. Finetti, Jyoti Choudhary, Ian Judson, Cyril F. Fisher, Eugene Schuster, Anguraj W. Sadanandam, Tom Chen, Daniel Williamson, Khin L. Thway, Robin Jones, Maggie C. U. H. Cheang, Paul Huang
Summary: This study conducted comprehensive proteomic profiling of tumor specimens from 321 STS patients and identified three proteomic subtypes within leiomyosarcomas with distinct myogenesis and immune features, anatomical site distribution and survival outcomes. The complement cascade is suggested as a candidate immunotherapeutic target for undifferentiated pleomorphic sarcomas and dedifferentiated liposarcomas. The study also defines functional signatures called Sarcoma Proteomic Modules that are independent prognostic factors for distant metastasis.
NATURE COMMUNICATIONS
(2023)
Meeting Abstract
Oncology
Eugene F. Schuster, Elena Lopez-Knowles, Anastasia Alataki, Lila Zabaglo, Elizabeth Folkerd, David Evans, Kally Sidhu, Holly Tovey, Perry Maxwell, Nicholas Turner, Stephen Johnston, Manuel Salto-Tellez, Maggie Chon U. Cheang, John Robertson, Ian Smith, Judith Bliss, Mitch Dowsett
Meeting Abstract
Oncology
Holly Tovey, Orsolya Sipos, Katherine A. Hoadley, Joel S. Parker, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Andrew Tutt, Anita Grigoriadis, Maggie Chon U. Cheang
Meeting Abstract
Oncology
Xixuan Zhu, Hui Xiao, Elena Lopez-Knowles, Milana A. Bergamino Sirven, Anastasia Alataki, Perry Maxwell, Holly Tovey, Lucy Kilburn, Chris Holcombe, Anthony Skene, Ian Smith, John Robertson, Katherine A. Hoadley, Roberto Salgado, Judith Bliss, Nicholas Turner, Manuel Salto-Tellez, Gene Schuster, Mitch Dowsett, Maggie Chon U. Cheang
Meeting Abstract
Oncology
Maggie Chon U. Cheang, Monisha Dewan, Lucy Kilburn, Gabriele Morani, Lila Zabaglo, Kally Sidhu, Holly Tovey, Xixuan Zhu, Chris Holcombe, Anthony Skene, Ian Smith, John Robertson, Alistair Ring, Nicholas Turner, Judith Bliss, Mitch Dowsett
Meeting Abstract
Oncology
Anastasia Alataki, Gene Schuster, Lila Zabaglo, Perry Maxwell, Elena Lopez-Knowles, Elizabeth Folkerd, David Evans, Kally Sidhu, Holly Tovey, Nicholas Turner, Stephen Johnston, Maggie Chon U. Cheang, John Robertson, Manuel Salto-Tellez, Ian Smith, Judith Bliss, Mitch Dowsett
Article
Oncology
Elena Lopez-Knowles, Simone Detre, Margaret Hills, Eugene F. Schuster, Maggie C. U. Cheang, Holly Tovey, Lucy S. Kilburn, Judith M. Bliss, John Robertson, Elizabeth Mallon, Anthony Skene, Abigail Evans, Ian Smith, Mitch Dowsett
Summary: The study aimed to assess the relationship between IHC and mRNA cut-points for ER and the biological response of primary breast cancer to aromatase inhibitor treatment. Little responsiveness was observed at IHC < 10% without distinction between < 1% and 1-10% cells positive.
BREAST CANCER RESEARCH
(2022)